ECSP034888A - Conjugados inmunogenicos de bajo peso molecular de acido halurónico con toxinas polipeptidas - Google Patents
Conjugados inmunogenicos de bajo peso molecular de acido halurónico con toxinas polipeptidasInfo
- Publication number
- ECSP034888A ECSP034888A EC2003004888A ECSP034888A ECSP034888A EC SP034888 A ECSP034888 A EC SP034888A EC 2003004888 A EC2003004888 A EC 2003004888A EC SP034888 A ECSP034888 A EC SP034888A EC SP034888 A ECSP034888 A EC SP034888A
- Authority
- EC
- Ecuador
- Prior art keywords
- molecular weight
- streptococci
- group
- low
- hyaluronic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
La presente invención provee composiciones antigénicas y métodos para el tratamiento y prevención de infecciones y enfermedades causadas por estreptococos de los grupos A y C. En particular la invención provee de ácido hialurónico de bajo peso molecular, unido a un portador y composiciones que los comprenden. Los compuestos obtienen anticuerpos de bajo peso molecular de ácido hialurónico los cuales son contra reactivos con los estreptococos de grupos A y C y que son mínimamente contra-reactivos con el ácido hialurónico nativo. La invención es particularmente útil para proveer protección inmunogénica tanto activa como pasiva en aquellos infectados o con riesgo de infección por estreptococos de grupos A y C. Adicionalmente la presente invención provee métodos y composiciones útiles para el diagnóstico de infecciones y enfermedades causadas por estreptococos de grupos A y C.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/853,367 US20020192205A1 (en) | 2001-05-11 | 2001-05-11 | Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP034888A true ECSP034888A (es) | 2004-05-28 |
Family
ID=25315838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2003004888A ECSP034888A (es) | 2001-05-11 | 2003-12-11 | Conjugados inmunogenicos de bajo peso molecular de acido halurónico con toxinas polipeptidas |
Country Status (15)
Country | Link |
---|---|
US (1) | US20020192205A1 (es) |
EP (1) | EP1385554A2 (es) |
JP (1) | JP2005508854A (es) |
KR (1) | KR20030096369A (es) |
CN (1) | CN1525869A (es) |
AR (1) | AR034331A1 (es) |
BR (1) | BR0209562A (es) |
CA (1) | CA2446555A1 (es) |
CO (1) | CO5550467A2 (es) |
EC (1) | ECSP034888A (es) |
HU (1) | HUP0400840A3 (es) |
MX (1) | MXPA03010283A (es) |
PL (1) | PL366692A1 (es) |
SK (1) | SK15122003A3 (es) |
WO (1) | WO2002092131A2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2251699C1 (ru) * | 2003-09-25 | 2005-05-10 | Киселев Всеволод Иванович | Способ ранней и доклинической диагностики цервикального рака |
JP4576583B2 (ja) * | 2005-03-22 | 2010-11-10 | キユーピー株式会社 | ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物 |
US20070225484A1 (en) * | 2006-03-25 | 2007-09-27 | Framroze Bomi P | Process for the Isolation and Stabilization of Low-Molecular Weight Aminoglycans from Waste Egg Shells |
US8529951B1 (en) | 2007-02-21 | 2013-09-10 | Anand Ramamurthi | Elastogenic cues and methods for using same |
US9687559B2 (en) | 2008-03-19 | 2017-06-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
US9925209B2 (en) | 2008-03-19 | 2018-03-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same |
EP2341941A4 (en) * | 2008-09-09 | 2014-12-10 | Univ Oklahoma | HEPAROSANE POLYMERS AND METHODS OF MAKING AND USING THEM TO ENHANCE THERAPEUTIC COMPOUNDS |
HUE029265T2 (en) * | 2008-10-27 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Method of purifying carbohydrates from the group streptococci |
CN102010469B (zh) * | 2010-10-22 | 2013-02-27 | 上海贝西生物科技有限公司 | 一种抗透明质酸单克隆抗体及其用途 |
WO2013119061A1 (ko) * | 2012-02-07 | 2013-08-15 | 포항공과대학교 산학협력단 | 경피 전달용 히알루론산-단백질 컨쥬게이트의 제조 방법 및 이에 따라 제조된 경피 전달용 히알루론산-단백질 컨쥬게이트 |
CN104237500B (zh) * | 2014-09-30 | 2016-09-28 | 博奥赛斯(天津)生物科技有限公司 | 一种透明质酸固相包被方法 |
SG11201908650PA (en) | 2017-03-22 | 2019-10-30 | Genentech Inc | Optimized antibody compositions for treatment of ocular disorders |
CN115590774B (zh) * | 2022-10-20 | 2024-05-03 | 珠海原妙医学科技股份有限公司 | 透明质酸脂质体组装体及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
JPH0912600A (ja) * | 1995-06-22 | 1997-01-14 | Shiseido Co Ltd | ヒアルロン酸ナトリウムに対するモノクローナル抗体及びその製造方法 |
PL338146A1 (en) * | 1997-07-17 | 2000-09-25 | North American Vaccine | Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide |
WO1999062546A1 (en) * | 1998-06-01 | 1999-12-09 | Chiron Corporation | Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants |
-
2001
- 2001-05-11 US US09/853,367 patent/US20020192205A1/en not_active Abandoned
-
2002
- 2002-05-10 AR ARP020101723A patent/AR034331A1/es not_active Application Discontinuation
- 2002-05-10 JP JP2002589047A patent/JP2005508854A/ja not_active Withdrawn
- 2002-05-10 BR BR0209562-9A patent/BR0209562A/pt not_active IP Right Cessation
- 2002-05-10 PL PL02366692A patent/PL366692A1/xx not_active Application Discontinuation
- 2002-05-10 CN CNA028139437A patent/CN1525869A/zh active Pending
- 2002-05-10 KR KR10-2003-7014583A patent/KR20030096369A/ko not_active Application Discontinuation
- 2002-05-10 MX MXPA03010283A patent/MXPA03010283A/es not_active Application Discontinuation
- 2002-05-10 SK SK1512-2003A patent/SK15122003A3/sk unknown
- 2002-05-10 WO PCT/EP2002/005310 patent/WO2002092131A2/en not_active Application Discontinuation
- 2002-05-10 HU HU0400840A patent/HUP0400840A3/hu unknown
- 2002-05-10 CA CA002446555A patent/CA2446555A1/en not_active Abandoned
- 2002-05-10 EP EP02750926A patent/EP1385554A2/en not_active Withdrawn
-
2003
- 2003-11-11 CO CO03099742A patent/CO5550467A2/es not_active Application Discontinuation
- 2003-12-11 EC EC2003004888A patent/ECSP034888A/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR0209562A (pt) | 2004-03-30 |
WO2002092131A3 (en) | 2003-03-20 |
PL366692A1 (en) | 2005-02-07 |
EP1385554A2 (en) | 2004-02-04 |
HUP0400840A2 (hu) | 2004-07-28 |
US20020192205A1 (en) | 2002-12-19 |
MXPA03010283A (es) | 2004-12-06 |
AR034331A1 (es) | 2004-02-18 |
JP2005508854A (ja) | 2005-04-07 |
HUP0400840A3 (en) | 2004-10-28 |
SK15122003A3 (sk) | 2004-10-05 |
CN1525869A (zh) | 2004-09-01 |
WO2002092131A2 (en) | 2002-11-21 |
CO5550467A2 (es) | 2005-08-31 |
CA2446555A1 (en) | 2002-11-21 |
KR20030096369A (ko) | 2003-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP044933A (es) | Método y montaje para aumentar el volumen del cabello | |
ECSP034888A (es) | Conjugados inmunogenicos de bajo peso molecular de acido halurónico con toxinas polipeptidas | |
BR0315937A (pt) | Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo | |
EA200801570A1 (ru) | Стабильные белковые препараты | |
CO2021005226A2 (es) | Nuevos compuestos antihelmínticos | |
BRPI0208183B8 (pt) | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer | |
BR0210838A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase-3, e de doenças, e medicação contraceptiva, e, processos para a preparação de um composto | |
BRPI0212999B1 (pt) | novas composições imunogênicas para a prevenção e tratamento de doença meningocócica | |
WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
BR9914638A (pt) | Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo | |
BRPI0515516A (pt) | composição imunogênica, vacina, métodos de fabricar uma vacina e de prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, método de preparar um globulina imune para uso na prevenção ou tratamento de infecção estafilocócica, composição farmacêutica, e, uso da composição farmacêutica | |
BRPI0905687A8 (pt) | composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto | |
ECSP045353A (es) | Derivados de benzoxazinona, su preparación y aplicación como medicamentos | |
EA202091690A1 (ru) | Иммуногенная композиция, содержащая стафилококковые антигены | |
DOP2022000171A (es) | Compuestos tetracíclicos para el tratamiento de infecciones por vih | |
BRPI0416376A (pt) | composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes | |
BR0309753A (pt) | Processo para a preparação de derivados de 6-alquilideno penem | |
ATE539153T1 (de) | Primaten t-lymphotrophische viren | |
UA107177C2 (uk) | Імуногенна композиція цвс2 та спосіб приготування такої композиції | |
BR112014007491A2 (pt) | sequências de aminoácidos para o controle de patógenos | |
BR0203949A (pt) | Polipeptìdeo se36, processo para purificação do polipeptìdeo se36, vacina para malária, agente de diagnóstico para malária e fragmento de dna sintético | |
BR0014666A (pt) | Vacina | |
BR112015013625A2 (pt) | adjuvante de vacinação, preparação e vacinas contendo o mesmo | |
BRPI0414139A (pt) | métodos e composições para tratar infecções por herpes | |
BRPI0407271A (pt) | Composição anti-helmìntica |